

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

(1) RESIGNATION OF EXECUTIVE DIRECTOR; (2) CHANGE OF CHAIRMAN AND AUTHORISED REPRESENTATIVE; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") hereby announces that Mr. Zhang Shuguang ("**Mr. Zhang**") has tendered his resignation as an executive Director ("**ED**"), the chairman of the Board (the "**Chairman**"), the chairman of nomination committee (the "**Nomination Committee**") and an authorised representative (the "**Authorised Representative**") of the Company under Rule 5.24 of the Rules Governing the Listing of Securities on GEM (the "**GEM Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") with effect from 29 August 2025, as, after discussion with the Board, he intended to devote more time to focus on the management of the business of the subsidiaries of the Company, rather than to focus on the Company's executive functions. After his resignation as an ED, Mr. Zhang will remain as a director of certain subsidiaries of the Company.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

Notwithstanding the resignation of Mr. Zhang, his obligations under a deed of personal guarantee executed on 21 March 2023 in favour of the Group shall remain unchanged. For further details, please refer to the Company's interim report published on 21 August 2025 and the Company's announcements dated 6 January 2023, 7 February 2023, 9 February 2023, 30 June 2023, 28 March 2024 and 14 May 2024.

The Board would like to express its sincere gratitude for the valuable contribution that Mr. Zhang has made to the Company during his tenure of service.

CHANGE OF CHAIRMAN AND AUTHORISED REPRESENTATIVES AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board further announces that with effect from 29 August 2025, after considering the recommendation of the Nomination Committee, Ms. Zhang Yujing, an ED, has been appointed as the Chairman. She has been also appointed as an Authorised Representative and the chairman of the Nomination Committee, in place of Mr. Zhang following his resignation, with effect from 29 August 2025.

Ms. Zhang, aged 41, was appointed as an ED with effect from 16 April 2025. Since 2023, Ms. Zhang has served as a general manager of Hunan Keyue Biotechnology Co., Ltd. (湖南可悅生物科技股份有限公司)(“**Keyue Bio**”), a company engaged in the research and development and sales of women’s health products. From 2013 to 2023, Ms. Zhang was a general manager of Hua’entang Health Management (Changsha) Company Limited (華恩堂養生管理(長沙)有限公司), a company engaged in providing health and wellness consultation services and research and development of health supplements. Prior to that, she served as a research assistant of the Institute of Molecular Medicine and Therapeutics* (分子藥物與治療研究所) at Central South University (中南大學) in the People’s Republic of China from March 2007 to May 2013. Ms. Zhang graduated from Hunan Women's University (湖南女子學院 formerly known as 湖南女子職業大學) in the People’s Republic of China in 2007.

As at the date of the announcement, Ms. Zhang has 9% equity interest in Keyue Bio, a non-wholly owned subsidiary of the Company. For further details, please refer to the interim report of the Company published on 21 August 2025 and the announcements of the Company dated 16 April 2025, 30 April 2025 and 26 June 2025.

Ms. Zhang has entered into a service contract with the Company for an initial term of three years commencing from 16 April 2025 and will continue thereafter until terminated by either party serving not less than three month’s written notice to the other party. Pursuant to the service contract, Ms. Zhang is entitled to a director’s emolument of HK\$240,000 per annum. Such fee is determined by the Board based on the recommendation of the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to her experience, responsibilities, workload and time devoted to the Company and will be subject to review by the remuneration committee from time to time. Save as disclosed above, Ms. Zhang is not expected to receive any other remuneration for holding her office as an ED.

In accordance with the articles of association of the Company, Ms. Zhang will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Ms. Zhang will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Save as disclosed above, as at the date of this announcement, Ms. Zhang (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any information which is disclosable nor is/was Ms. Zhang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited and there are no other matters concerning Ms. Zhang that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its welcome to Ms. Zhang on her new roles on the Board.

* English translation is for identification purpose only

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Yujing
Chairman and Executive Director

Hong Kong, 29 August 2025

As at the date of this announcement, the Executive Directors are Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Ms. Zhang Yujing; the non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the independent non-executive directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.